化合物 GSK J4|T3100|TargetMol

GSK-J4
1373423-53-0

￥397 2mg 起订

￥617 5mg 起订

￥956 10mg 起订

上海更新日期：2024-12-12

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 GSK J4

英文名称：: GSK-J4

CAS号：: 1373423-53-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.98%

产品类别：: 抑制剂

货号：: T3100

Product Introduction

Bioactivity

名称	GSK-J4
描述	GSK-J4 (GSK J4 HCl) is a cell permeable prodrug of GSK-J1, a dual inhibitor of the H3K27me3/me2 demethylases JMJD3/KDM6B and UTX/KDM6A (IC50=8.6/6.6 μM). GSK-J4 induces endoplasmic reticulum stress-related apoptosis.
动物实验	GSK-J4 is prepared in DMSO and diluted 1/10 with ethanol.Six-to eight-week-old female C57BL/6 WT mice are injected by subcutaneous injection (s.c.) with 50 μg myelin oligodendrocyte glycoprotein 35-55 peptide (pMOG) emulsified in Complete Freund's Adjuvant (CFA) supplemented with heat-inactivated Mycobacterium tuberculosis H37 RA. In addition, mice receive intraperitoneal injection (i.p.) of 500 ng of pertussis toxin on days 0 and 2. Clinical signs are assessed daily according to the following scoring criteria: 0, no detectable signs; 1, flaccid tail; 2, hind limb weakness or abnormal gait; 3, complete hind limb paralysis; 4, paralysis of fore and hind limbs; and 5, moribund or death. A stock solution of GSK-J4 of 42 mg/mL (100 mM) is prepared in dimethyl sulfoxide (DMSO) to preserve stability. Before injection, the stock solution is diluted 1/10 with ethanol (DMSO: ethanol, 1:10 v/v) and brought to a final concentration of 140 μg/mL in PBS. In systemic drug evaluation experiments, each mouse receive daily i.p. injections (from days 0-5) of 100 μL of this solution containing 14.0 μg of the GSK-J4 (equivalent to 0.56 mg/kg of the drug). Control mice receive 100 μL of the vehicle during the same period. In other EAE experiments, 106 bone marrow-derived DCs from WT mice are treated with GSK-J4 or vehicle alone for 16 h, pulsed with 5 μg/mL of pMOG for 4 h and then transferred i.v. into WT C57BL/6 recipient mice 14 and 7 days before EAE induction. In other adoptive transfer EAE experiments, CD4+Foxp3+ Treg cells generated in the presence or absence of 25 nM GSK-J4 are purified by cell sorting and then 0.75×106 transferred i.v. into WT C57BL/6 recipient mice 1 day before EAE induction.
体外活性	方法: 前列腺癌症细胞系 R1-AD1、R1-D567、R1-I567、CWR22Rv-1 和 PC3 用 GSK-J4 (0-32 µM) 处理 72 h，通过 Alamar blue reagent 检测细胞活力。结果: GSK-J4 对 PC 细胞具有细胞生长抑制和/或细胞毒性作用。CWR22Rv-1 对治疗最敏感，ED50 约为 3 µM。[1] 方法: 人急性髓系白血病细胞 KG-1a 用 GSK-J4 (2-10 µM) 处理 48 h，通过 Flow cytometry 检测细胞凋亡。结果: GSK-J4 治疗组 KG-1a 细胞的凋亡率与对照组相比显著增加。[2]
体内活性	方法: 为研究对败血症的作用，将 GSK-J4 (1-3 mg/kg) 腹腔注射给 ICR 小鼠，1 h 后注射细菌悬液诱导败血症。结果: GSKJ4 对 JMJD3 的药理学抑制保护小鼠免受早期败血症死亡，并减少促炎细胞因子 IL-1β 的产生以及 IL-6、TNF-α 和 MCP-1 的表达。[3]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : 41.75 mg/mL (100 mM) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4.18 mg/mL (10.01 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. DMSO : 60 mg/mL (143.71 mM)
关键字	GSKJ4 \| Inhibitor \| Apoptosis \| H3K27me3/me2 \| demethylase \| diabetic \| inflammation \| Th17 \| TGF-β \| mice \| cells \| GSK-J4 \| dendritic \| GSK-J-4 \| Histone Demethylase \| inhibit \| Th1 \| GSK J4
相关产品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 经典已知活性库 \| 已知活性化合物库 \| 染色质修饰分子库 \| 组蛋白修饰化合物库 \| 细胞凋亡化合物库 \| NO PAINS 化合物库 \| 表观遗传库 \| 甲基化化合物库 \| 内质网应激化合物库

GSK J4 HCl|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务